Stock Market Review ASX:MEM Memphasys
Part of a series on small cap stocks.
This stock caught my eye after a price spike. Turns out this stock has a lot of potential and has signs of being missed.
Memphasys is developing and commercialising innovative separation techniques using the Company’s proprietary membrane technology to bio-separate sperm for IVF. The key benefit for IVF is increased safety in selection of highest quality sperm and represents a significent improvement over existing methods.
More than 70 million couples worldwide cannot conceive naturally and must use assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), or in vitro fertilization (IVF).
In nearly 50% of cases, the problem is attributable to male factors. The frequency of male infertility is on the rise and is driving an increasing need for solutions to improve the outcome of ART procedures.
